JP2005512558A5 - - Google Patents

Download PDF

Info

Publication number
JP2005512558A5
JP2005512558A5 JP2003553988A JP2003553988A JP2005512558A5 JP 2005512558 A5 JP2005512558 A5 JP 2005512558A5 JP 2003553988 A JP2003553988 A JP 2003553988A JP 2003553988 A JP2003553988 A JP 2003553988A JP 2005512558 A5 JP2005512558 A5 JP 2005512558A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cap
group
tables
sequence selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003553988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512558A (ja
Filing date
Publication date
Priority claimed from US10/034,650 external-priority patent/US20030216558A1/en
Application filed filed Critical
Publication of JP2005512558A publication Critical patent/JP2005512558A/ja
Publication of JP2005512558A5 publication Critical patent/JP2005512558A5/ja
Pending legal-status Critical Current

Links

JP2003553988A 2001-12-20 2002-12-20 癌のための新規の組成物および方法 Pending JP2005512558A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/034,650 US20030216558A1 (en) 2000-12-22 2001-12-20 Novel compositions and methods for cancer
PCT/US2002/041776 WO2003053224A2 (en) 2001-12-20 2002-12-20 Novel compositions and methods for cancer

Publications (2)

Publication Number Publication Date
JP2005512558A JP2005512558A (ja) 2005-05-12
JP2005512558A5 true JP2005512558A5 (https=) 2006-01-26

Family

ID=21877742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003553988A Pending JP2005512558A (ja) 2001-12-20 2002-12-20 癌のための新規の組成物および方法

Country Status (6)

Country Link
US (1) US20030216558A1 (https=)
EP (1) EP1469769A4 (https=)
JP (1) JP2005512558A (https=)
AU (2) AU2002364052B2 (https=)
CA (1) CA2470844A1 (https=)
WO (1) WO2003053224A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030064377A1 (en) * 2000-11-06 2003-04-03 Yongming Sun Compositions and methods relating to prostate specific genes and proteins
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
GB0703887D0 (en) * 2007-02-28 2007-04-11 Bakhiet Abdelmoiz Immune system mediator
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Lingo‐1拮抗薬及び脱髄障害の治療のための使用
CN119757761B (zh) * 2024-12-16 2026-03-06 新疆医科大学第一附属医院 一种鉴别诊断活动性肺结核的生物标志物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2416292A1 (en) * 2000-06-29 2002-01-10 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
US20030044812A1 (en) * 2001-01-18 2003-03-06 Walker Michael G. Cell differentiation cDNAs induced by retinoic acid
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US20030049623A1 (en) * 2001-07-18 2003-03-13 Shi Huang PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2005514923A5 (https=)
JP2005512558A5 (https=)
EA020795B1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
KR101651690B1 (ko) Vegf 다형성 및 항―혈관신생 요법
JP2006518991A5 (https=)
JP6496003B2 (ja) Fgf−18化合物に対する応答性を予測するための遺伝子マーカー
KR20160138494A (ko) Fgfr 융합물
CN104703620A (zh) 诊断和治疗方法
JP2005522999A5 (https=)
JP2015535172A (ja) 軟骨障害の予後バイオマーカー
Mahon et al. Is persistent adenovirus 12 infection involved in coeliac disease? A search for viral DNA using the polymerase chain reaction.
JP2006518186A5 (https=)
CN105659085A (zh) 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法
JP2008512984A5 (https=)
WO2016042114A1 (en) Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
JP2005511023A5 (https=)
CA2376666A1 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
JP2005531290A5 (https=)
JP2005535289A5 (https=)
JP2008514925A5 (https=)
JP2005526508A5 (https=)
JP2006501465A5 (https=)
JP2005538692A5 (https=)
JP2009523004A5 (https=)
WO2017079695A1 (en) Gene expression patterns to predict responsiveness to virotherapy in cancer indications